HOOKIPA Pharma Inc
HOOK0.840USD
0.000
Market hours （ET）Quotes delayed by 15 min
10.14MMarket Cap
LossP/E TTM
More Details of HOOKIPA Pharma Inc Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
HOOKIPA Pharma Inc Info
Ticker SymbolHOOK
Company nameHOOKIPA Pharma Inc
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Number of employees82
Security typeOrdinary Share
Fiscal year-endApr 18
Address350 Fifth Avenue, 72Nd Floor, Suite 7240
CityNEW YORK
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code10118
Phone114318906360
Websitehttps://www.hookipapharma.com/
Ticker SymbolHOOK
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Company Executives of HOOKIPA Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
18.89%
Baker Bros. Advisors LP
8.18%
Invus Public Equities Advisors, LLC
5.71%
Knoll Capital Management, LLC
5.02%
Fidelity Management & Research Company LLC
3.24%
Other
58.95%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
18.89%
Baker Bros. Advisors LP
8.18%
Invus Public Equities Advisors, LLC
5.71%
Knoll Capital Management, LLC
5.02%
Fidelity Management & Research Company LLC
3.24%
Other
58.95%
Shareholder Types
Shareholders
Proportion
Corporation
18.89%
Hedge Fund
14.23%
Investment Advisor
12.75%
Venture Capital
3.16%
Investment Advisor/Hedge Fund
2.04%
Research Firm
0.31%
Individual Investor
0.13%
Other
48.48%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
82
3.23M
32.50%
-1.14M
2025Q2
100
5.23M
53.41%
-1.43M
2025Q1
107
5.24M
53.53%
-1.53M
2024Q4
113
5.54M
57.39%
-1.29M
2024Q3
117
5.65M
62.13%
+370.86K
2024Q2
126
5.73M
65.67%
+16.62K
2024Q1
159
5.79M
66.36%
+211.50K
2023Q4
171
5.72M
72.26%
+846.00
2023Q3
186
4.97M
68.46%
-1.10M
2023Q2
191
5.35M
75.93%
+1.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
1.88M
18.89%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
812.81K
8.18%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
566.64K
5.71%
--
--
Jun 30, 2025
Knoll Capital Management, LLC
498.63K
5.02%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
322.22K
3.24%
-14.24K
-4.23%
Jun 30, 2025
Sofinnova Partners
314.26K
3.16%
+314.26K
--
Feb 14, 2025
The Vanguard Group, Inc.
300.82K
3.03%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
73.34K
0.74%
-91.00
-0.12%
Jun 30, 2025
Acadian Asset Management LLC
55.73K
0.56%
--
--
Jun 30, 2025
Ikarian Capital LLC
53.00K
0.53%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Date
Type
Ratio
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
